Validated across 50 immunotherapy cohorts (52 treatment arms) spanning 16 cancer types, IMIREG robustly predicts clinical benefit (mean AUROC = 0.71), consistently outperforming established response and resistance signatures, including the T cell-inflamed, IFN-γ, CD8 T effector, and antigen presentation signatures. This evidence concerns the gene CD8A and cancer.